Therapeutic Drug Monitoring of Pazopanib in Renal Cell Carcinoma and Soft Tissue Sarcoma: A Systematic Review

Varování

Publikace nespadá pod Filozofickou fakultu, ale pod Lékařskou fakultu. Oficiální stránka publikace je na webu muni.cz.
Autoři

TURJAP Miroslav PELCOVÁ Marta GREGOROVÁ Jana ŠMAK Pavel MARTIN Hiroko ŠTINGL Jan PEŠ Ondřej JUŘICA Jan

Rok publikování 2024
Druh Článek v odborném periodiku
Časopis / Zdroj THERAPEUTIC DRUG MONITORING
Fakulta / Pracoviště MU

Lékařská fakulta

Citace
www https://journals.lww.com/drug-monitoring/abstract/2024/06000/therapeutic_drug_monitoring_of_pazopanib_in_renal.7.aspx
Doi http://dx.doi.org/10.1097/FTD.0000000000001206
Klíčová slova pazopanib; renal cell carcinoma; soft tissue sarcoma; therapeutic drug monitoring; toxicity-adjusted dosing
Přiložené soubory
Popis Background: Pazopanib, an anti-angiogenic multitarget tyrosine kinase inhibitor, has been approved for the treatment of metastatic renal cell carcinoma and soft tissue sarcoma. However, its recommended dose does not always produce consistent outcomes, with some patients experiencing adverse effects or toxicity. This variability is due to differences in the systemic exposure to pazopanib. This review aimed to establish whether sufficient evidence exists for the routine or selective therapeutic drug monitoring of pazopanib in adult patients with approved indications. Methods: A systematic search of the PubMed and Web of Science databases using search terms related to pazopanib and therapeutic drug monitoring yielded 186 and 275 articles, respectively. Ten articles associated with treatment outcomes or toxicity due to drug exposure were selected for review. Results: The included studies were evaluated to determine the significance of the relationship between drug exposure/Ctrough and treatment outcomes and between drug exposure and toxicity. A relationship between exposure and treatment outcomes was observed in 5 studies, whereas the trend was nonsignificant in 4 studies. A relationship between exposure and toxicity was observed in 6 studies, whereas 2 studies did not find a significant relationship; significance was not reported in 3 studies. Conclusions: Sufficient evidence supports the therapeutic drug monitoring of pazopanib in adult patients to improve its efficacy and/or safety in the approved indications.

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.